Essential cookies by default. The browser ID, load-time metrics and error replays only run if you choose "Accept all".
Head-to-head evidence comparison — which supplement is right for you?
Exenatide vs Pramlintide: Exenatide has the stronger overall evidence (6 vs 5/10); they're alternatives for manage blood sugar — the best pick depends on your goals. Take the 2-minute quiz for a pick tailored to your goals.
Exenatide wins 2 of 3 categories.
Verdict
Too few graded studies
1 of 1 studies with measurable effects showed benefit.
Top outcomes
Verdict
Too few graded studies
1 of 1 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (3)
Outcomes where both Exenatide and Pramlintide have evidence — compare verdict strength side-by-side.
Prescription-only, clinician-directed. Subcutaneous. Byetta (twice-daily): 5 µg before two main meals, escalated to 10 µg after ~1 month. Bydureon (once-weekly extended-release): 2 mg subcutaneously once weekly. DO NOT self-dose.
Any time of day
Once-weekly extended-release injection (Bydureon)
Prescription-only, clinician-titrated. Subcutaneous injection immediately before major meals. Type 1 diabetes: typically start 15 µg and titrate to 30-60 µg per meal. Type 2 diabetes (on mealtime insulin): typically start 60 µg and titrate to 120 µg per meal. Reduce mealtime insulin (often by ~50%) when starting. DO NOT self-dose.
With meals
Subcutaneous pre-meal injection (Symlin / SymlinPen)
and 1 more not shown
and 1 more not shown
Both entries document blood-sugar lowering. Two agents carrying the same documented risk may add up, so this pair is flagged as a caution to prompt a review of the combined exposure. That follows from a general rule, not from a study of this specific combination, and it is not evidence that the combination causes harm.
Discuss it with a healthcare provider.
Weeks to months
Months
Years
Especially early / during dose escalation
Weeks to 6-12 months
Per meal / weeks
Months
The label describes severe hypoglycaemia, when it occurs, within three hours after a Symlin injection; this is not a guarantee of no risk at other times.
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes (EXSCEL).
N Engl J Med (2017) · RCT · n=14752
Large cardiovascular-outcomes RCT: 14,752 patients with type 2 diabetes (73.1% with prior cardiovascular disease), once-weekly exenatide 2 mg vs placebo added to usual care, median 3.2 years
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes (DURATION-1): a randomised, open-label, non-inferiority study.
Lancet (2008) · RCT · n=295
30-week open-label RCT in 295 patients with type 2 diabetes comparing once-weekly extended-release exenatide 2 mg with 10 µg twice daily
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.
Lancet (2013) · RCT · n=911
26-week head-to-head open-label RCT in 911 patients: once-weekly exenatide 2 mg vs once-daily liraglutide 1.8 mg added to oral therapy
Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.
Diabet Med (2004) · RCT · n=651
Double-blind, placebo-controlled, parallel-group multicentre trial in 651 patients with type 1 diabetes, mealtime pramlintide at varying doses or placebo added to insulin for 52 weeks.
A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.
Diabetes Care (2002) · RCT · n=480
52-week double-blind, placebo-controlled trial in 480 patients with type 1 diabetes, pramlintide 30 µg four times daily or placebo added to insulin. At week 20, pramlintide patients whose HbA1c had fallen less than 1% by week 13 were re-randomised to 30 or 60 µg.
Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.
Diabetes Care (2003) · RCT · n=656
52-week double-blind, placebo-controlled, parallel-group multicentre trial in 656 insulin-treated patients with type 2 diabetes, randomised to placebo or pramlintide 60 µg three times daily, 90 µg twice daily or 120 µg twice daily.
Exenatide has a higher evidence score (6/10 vs 5/10) and wins in 2 of 3 categories.
For manage blood sugar, Exenatide has a higher relevance score (66 vs 56).
Both entries document blood-sugar lowering. Two agents carrying the same documented risk may add up, so this pair is flagged as a caution to prompt a review of the combined exposure. That follows from a general rule, not from a study of this specific combination, and it is not evidence that the combination causes harm. Discuss it with a healthcare provider. Consult a healthcare provider for personalized advice.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.